Get the Stockscreener App
104.24
0.66%
-0.69
Pre-market:
103.20
-1.04
-1.00%
Boston Scientific Corp stock is traded at $104.24, with a volume of 4.82M.
It is down -0.66% in the last 24 hours and up +16.21% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$104.93
Open:
$104.54
24h Volume:
4.82M
Relative Volume:
0.59
Market Cap:
$151.13B
Revenue:
$17.55B
Net Income/Loss:
$2.03B
P/E Ratio:
76.09
EPS:
1.37
Net Cash Flow:
$2.72B
1W Performance:
+2.02%
1M Performance:
+16.21%
6M Performance:
+21.86%
1Y Performance:
+43.09%
1-Day Range:
$103.54
$104.81
1-Week Range:
$101.46
$105.54
52-Week Range:
$71.88
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Are Wall Street Analysts Predicting Boston Scientific Stock Will Climb or Sink? - Nasdaq
Are Wall Street Analysts Predicting Boston Scientific Stock Will Climb Or Sink? - Barchart.com
Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan - ADVFN
Boston Scientific, FDA Sued Over 'Unsafe' Spinal Implant - Law360
A Changing of the Guard at Boston Scientific, Wright Medical Group and Vision-Sciences - Medical Product Outsourcing
Can Boston Scientific Corporation (NYSE:BSX) Performance Keep Up Given Its Mixed Bag Of Fundamentals? - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Boston Scienti - GuruFocus
$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today - Benzinga
June 13th Options Now Available For Boston Scientific (BSX) - Nasdaq
BOSTON SCIENTIFIC CORP SEC 10-Q Report - TradingView
Here are the highest-paid Mass. life sciences CEOs - The Business Journals
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Zacks Investment Ideas Feature Highlights: Boston Scientific, Meta Platforms And Microsoft - Barchart.com
Boston Scientific Announces Results for Second Quarter 2024 - Quantisnow
Indexes Take A Well-Deserved Pause; SAP, Boston Scientific, Credicorp In Focus - Investor's Business Daily
EMEA Growth & Product Launches to Support Boston Scientific Stock - MSN
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific And Medtronic - Barchart.com
The Zacks Analyst Blog Highlights Walmart, Toyota Motor, Boston Scientific and Autoscope - Yahoo Finance
Boston Scientific has positive ICD, Watchman FLX, AI data - MassDevice
Top Stock Reports for Walmart, Toyota Motor & Boston Scientific - MSN
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now - Yahoo Finance
Boston Scientific CFO Dan Brennan to retire after nearly 30 years with the company - MedTech Dive
Boston Scientific reports outcomes from Farapulse and Farapoint trial - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Barclays Followin - GuruFocus
Boston Sci expects $200M tariff hit, still raises guidance - BioWorld MedTech
Boston Scientific has positive Farapulse, Farapoint data - MassDevice
Boston Scientific (BSX) Reports Positive Results for FARAPULSE S - GuruFocus
Boston Scientific (BSX) Reports Positive Results for FARAPULSE System in Atrial Fibrillation Study | BSX Stock News - GuruFocus
Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints – Company AnnouncementFT.com - Financial Times
Boston Scientific (NYSE:BSX) Announces CFO Retirement And Strong Earnings Growth - Yahoo Finance
Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results - Benzinga
Global Neuroprosthetics Market Expanding Rapidly at a CAGR of ~13% by 2032 Amid Surge in Demand for Advanced Neurological Treatments | DelveInsight - GlobeNewswire Inc.
Boston Scientific's Heart Device Success Lifts 2025 Profit Forecast - Finimize
Boston Scientific (BSX) Price Target Raised to $117 by Truist An - GuruFocus
RBC Capital lifts Boston Scientific stock target to $120 - Investing.com
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term - Nasdaq
Boston Scientific (BSX) Price Target Raised by Baird Amid Strong Q1 Performance | BSX Stock News - GuruFocus
Boston Scientific (BSX) Target Price Boosted by RBC Capital Afte - GuruFocus
Canaccord maintains Buy rating on Boston Scientific stock - Investing.com
Raymond James Adjusts Boston Scientific (BSX) Price Target, Reaffirms Strong Buy | BSX Stock News - GuruFocus
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Earnings Call Transcript - Insider Monkey
Canaccord maintains Buy rating on Boston Scientific stock By Investing.com - Investing.com UK
Boston Scientific Stock (BSX): Solid Q1 Earnings Growth - Value The Markets
Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split - The Business Journals
Boston Scientific Corp (BSX) Q1 2025 Earnings Call Highlights: Strong Growth and Upgraded ... - Yahoo Finance
Boston Scientific Reports Strong Q1 2025 Growth - TipRanks
Boston Scientific: Q1 Earnings Snapshot - CT Insider
Boston Scientific Reports Strong Earnings Amid Challenges - TipRanks
Data backs Boston Scientific drug-eluting stent - MassDevice
BTIG Raises Price Target for Boston Scientific (BSX) to $124 Ami - GuruFocus
BTIG Raises Price Target for Boston Scientific (BSX) to $124 Amid Strong Outlook | BSX Stock News - GuruFocus
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):